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FAM13A affects body fat distribution and
adipocyte function
Mohsen Fathzadeh 1,2,3,14, Jiehan Li1,2,3,14, Abhiram Rao1,4,14, Naomi Cook 5, Indumathi Chennamsetty1,2,
Marcus Seldin 6, Xiang Zhou1,2, Panjamaporn Sangwung 1,2,3, Michael J. Gloudemans 7, Mark Keller8,
Allan Attie 8, Jing Yang 9, Martin Wabitsch10, Ivan Carcamo-Orive 1,2,3, Yuko Tada 1,2,
Aldons J. Lusis 6, Myung Kyun Shin11, Cliona M. Molony11, Tracey McLaughlin3,12, Gerald Reaven1,2,3,
Stephen B. Montgomery 3,7,12,13, Dermot Reilly 11, Thomas Quertermous 1,2,3, Erik Ingelsson 1,2,3,15✉ &
Joshua W. Knowles 1,2,3,15✉
Genetic variation in the FAM13A (Family with Sequence Similarity 13 Member A) locus has
been associated with several glycemic and metabolic traits in genome-wide association
studies (GWAS). Here, we demonstrate that in humans, FAM13A alleles are associated with
increased FAM13A expression in subcutaneous adipose tissue (SAT) and an insulin
resistance-related phenotype (e.g. higher waist-to-hip ratio and fasting insulin levels, but
lower body fat). In human adipocyte models, knockdown of FAM13A in preadipocytes
accelerates adipocyte differentiation. In mice, Fam13a knockout (KO) have a lower visceral to
subcutaneous fat (VAT/SAT) ratio after high-fat diet challenge, in comparison to their wild-
type counterparts. Subcutaneous adipocytes in KO mice show a size distribution shift toward
an increased number of smaller adipocytes, along with an improved adipogenic potential. Our
results indicate that GWAS-associated variants within the FAM13A locus alter adipose
FAM13A expression, which in turn, regulates adipocyte differentiation and contribute to
changes in body fat distribution.
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Excess adiposity is known to be a key contributing factor tothe development of insulin resistance (IR), type 2 diabetes(T2D), dyslipidemia, and cardiovascular disease (CVD)1.
Body mass index (BMI) is a measure of adiposity1. However, not
all obese individuals (BMI ≥30 kg/m2) suffer from metabolic
complications (i.e. metabolically healthy obese). Concurrently,
not all normal-weight individuals (18.5 kg/m2 ≤ BMI ≤ 25 kg/m2)
are protected from metabolic comorbidities (i.e. metabolically
obese normal weight)2. Recently, we and others1,3,4 identified a
cluster of common risk variants from genome-wide association
studies (GWAS) that are associated with normal or lower adip-
osity and, at the same time, with a poorer cardiometabolic profile
(e.g. increased fasting insulin (FI), increased triglycerides, and
decreased HDL-cholesterol levels), resembling a normal weight
but metabolically unhealthy phenotype. By using refined mea-
sures of body composition and fat distribution, follow-up analysis
shows that the lower BMI-associated variants are associated with
a higher waist-to-hip ratio (WHR) and visceral-to-subcutaneous
adipose tissue ratio (VAT/SAT), which is driven by a fat
deposition shift from subcutaneous depots around the hip to
visceral depots around the waist5. Among these unfavorable fat
distribution risk loci are variants located in or near FAM13A
(Family With Sequence Similarity 13 Member A)4,5.
Common non-coding variants of FAM13A have been identified
in several GWAS of anthropometric and glycemic traits. For
instance, the same lead variant (rs3822072) is associated with
higher fasting insulin levels adjusted for BMI3 and lower HDL
cholesterol levels6. Another common non-coding FAM13A var-
iant (rs9991328, in high linkage disequilibrium [LD] with
rs3822072) is associated with increased WHR adjusted for BMI
(WHRadjBMI)1. However, the biological function of FAM13A in
this context is not fully understood. So far, FAM13A is best
known to be associated with human lung diseases, including
chronic obstructive pulmonary disease, asthma, and pulmonary
fibrosis7. A recent study also revealed an association between
FAM13A variants and liver cirrhosis8. Given that FAM13A is
highly expressed in human adipose tissue9, we hypothesized that
a comprehensive study combining human genetics with in vivo
and in vitro experiments focusing on adipose tissue would
uncover the biological mechanism linking FAM13A with body fat
distribution.
Here, we first explore the phenotypic effects of alleles within
the FAM13A locus using human genomic and adipose gene
expression datasets. Secondly, we perform in vitro loss-of-
function studies in human adipocytes to investigate the cell-
autonomous effect of FAM13A on adipocyte biology. Lastly, we
assess the effects of Fam13a knockout (KO) in mice on glucose
and lipid metabolism, adipocyte size and number distribution,
and overall gene expression in adipose tissue. Our human
genetics studies suggest that the disease risks conferred by the
FAM13A variants are mediated by a change in FAM13A
expression specifically in SAT. Our in vitro and in vivo experi-
mental studies show that FAM13A plays a role in adipocyte dif-
ferentiation and function.
Results
IR SNPs in FAM13A associate with higher FAM13A levels in
SAT. We performed fine-mapping and colocalization analyses to
explore several lines of evidence suggesting that non-coding
GWAS-associated variants in the FAM13A locus have functional
impact on FAM13A in adipose tissue. First, variants in the
FAM13A locus, including rs3822072, rs1377290, and rs9991328,
have been reported as lead variants within the locus across GWAS
studies of IR-related traits such as body fat percentage,
WHRadjBMI, fasting insulin levels. Next, these variants were
associated with FAM13A expression in subcutaneous adipose
tissue (SAT), but not in visceral adipose tissue (VAT; Fig. 1) in
data from the Genotype-Tissue Expression project (GTEx v7).
Finally, variants in the locus showed some evidence of enrich-
ment in regions annotated with the H3K27ac epigenetic mark in
adipose nuclei as compared to other tissues (Fig. 1). Bayesian
fine-mapping analysis of the SAT expression association signal
using the FINEMAP algorithm revealed that rs9991328, which is
associated with increased gene expression (b= 0.22 ± 0.03, p=
1e-08), had the highest posterior probability of driving the signal
(fine-mapping posterior probability= 0.66) among all the var-
iants in the region; we retained rs9991328 as the lead variant for
further analyses. This variant is located within an intronic region
~3.2 Mb away from the transcription start site of FAM13A. The
most commonly reported GWAS lead variant, rs3822072, was
among the top 5 variants in the fine-mapping analysis (posterior
probability= 0.06). In SAT, rs9991328 showed a robust associa-
tion with FAM13A expression (P= 1e-08) and was not a cis-
eQTL (expression quantitative trait locus) for any other genes
with transcription start sites within 1Mb of the variant. In con-
trast, rs9991328 showed a weaker association with FAM13A
expression (P > 1e-05) in VAT. The variant was also not a sig-
nificant trans-eQTL for any genes in adipose tissue (data from
GTEx v6p). Two-sided t-tests were used in cis-eQTL mapping. To
further evaluate whether FAM13A expression mediates the
genotype-phenotype associations at this locus, we performed
colocalization analysis of FAM13A gene expression in SAT, VAT,
liver, and skeletal muscle from GTEx (v7) with seven IR-related
GWAS traits using eCAVIAR10. We observed colocalizations
(posterior probability >0.8; lead variant rs9991328) between SAT
FAM13A expression and fasting insulin adjusted for BMI,
WHRadjBMI, triglycerides, and HDL-cholesterol. We did not
observe similar colocalizations or strong associations between
variants in the locus with gene expression in the other investi-
gated tissues, suggesting that FAM13A plays a specific role in SAT
(Fig. 1 and Supplementary Fig. 1). We also performed a
phenome-wide association study (PheWAS) in 337,536 indivi-
duals from the UK Biobank11,12 using the directly genotyped
variant rs1377290 as a proxy for the imputed variant rs9991328
(LD R2= 1.0). The rs1377290 T allele was associated with
increased WHR, and decreased trunk/body fat percentage, mean
platelet volume, and BMI (Fig. 2a). There were no other sig-
nificant associations across the phenotypic spectrum.
We then evaluated correlations of FAM13A expression data in
SAT with IR-related traits in the Metabolic Syndrome in Men
(METSIM)13,14 cohort. FAM13A expression levels in SAT
adjusted for BMI were positively correlated with WHR and
fasting insulin, and inversely correlated with fat mass (Fig. 2b).
These correlations replicate the genomic associations at the
FAM13A locus, where risk alleles resulting in higher SAT
FAM13A expression are associated with higher WHRadjBMI
and fasting insulin adjusted for BMI, and lower fat mass and BMI.
Pathway analysis with ConsensusPathDB15 using adipose expres-
sion data from the METSIM13 and STAGE16 cohorts showed that
mitochondria TCA cycle, lipid metabolism, cell cycle and Wnt-
signaling pathways were overrepresented in the genes correlated
with FAM13A (Supplementary Fig. 2).
Collectively, these human data support the notion that
FAM13A-increasing variants may predispose individuals to a
normal weight but metabolically unhealthy phenotype, while
decreased FAM13A is associated with favorable adiposity.
Considered jointly with GWAS studies, our results from
colocalization, eQTL and PheWAS analyses strongly indicate
that FAM13A is the causal gene in this locus, which prompted
further functional and metabolic assessments with a special focus
on the role of FAM13A in SAT.
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FAM13A knockdown effects on human adipocyte differentia-
tion. To translate the potential role of FAM13A into a human cell
model of adipocytes, we studied the expression and function of
FAM13A during the differentiation of Simpson-Golabi-Behmel
syndrome (SGBS) preadipocytes – a cell line isolated from sub-
cutaneous depots of an infant with SGBS17. Expression of
FAM13A was significantly increased during adipocyte differ-
entiation (Fig. 3a). FAM13A knockdown by siRNA in SGBS
preadipocytes (Fig. 3b) resulted in upregulation of adipogenesis
markers (e.g. CEBPA and PPARG) (Fig. 3c) as well as beige
adipogenic markers (e.g. PGC1A and UCP1) (Supplementary
Fig. 3A) in the early differentiation stage (Day 5). Following
90–95% of FAM13A knockdown achieved in preadipocytes by
CRISPR-interference (CRISPRi) (Fig. 3d), a similar induction of
adipogenic markers (CEBPA and PPARG) in early differentiating
adipocytes (Day 5) (Fig. 3e) confirmed a more active adipogenic
capability of FAM13A-deficient preadipocytes. To investigate the
impact of FAM13A on mature adipocyte function, we introduced
siRNAs in the late stage of adipocyte differentiation (Day 8) to
separate the confounding effect of FAM13A on adipogenesis.
Under this experimental timing and condition, although
FAM13A knockdown (Fig. 3f) did not significantly affect gene
expression of adipokines (e.g. ADIPOQ and LEP) (Supplementary
Fig. 3B) and lipolysis (Supplementary Fig. 3C), there was an
increased trend of glucose uptake into FAM13A-deficient SGBS
adipocytes under both basal and insulin-stimulated conditions
(Fig. 3g). Taken together, these results demonstrate that FAM13A
knockdown in human fat cells of subcutaneous origin may favor
adipocyte differentiation and function in glucose deposition.
Effect of Fam13a knockout on body fat distribution of mice.
Next, we investigated the metabolic consequences of whole-body
Fam13a loss in mice. Under normal chow-fed dietary conditions,
male WT and Fam13a KO mice showed no significant difference
in body weight (Supplementary Fig. 4A), mild decreases in
plasma concentrations of fasting glucose, insulin, free fatty acids,
and triglycerides (Supplementary Fig. 4B), and no change in
glucose or insulin tolerance tests (Supplementary Fig. 4C, D).
No differences in the above metabolic phenotypes were observed
between female WT and Fam13a KO mice (Supplementary
Fig. 5).
To explore the potential effects of FAM13A on the amount and
distribution of body fat, we assessed gross mass and histological
appearance of inguinal white adipose tissue (iWAT) and gonadal
white adipose tissue (gWAT) as representatives of SAT and
VAT, respectively. Neither the absolute amount of fat depots
(Supplementary Fig. 4E) nor the ratio of VAT/SAT (Supplementary
Fig. 4F) were different from WT to Fam13a KO mice on chow.
Normal histological appearance was maintained in Fam13a KO mice
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for both SAT and VAT (Fig. 4a). There was no significant difference
in total number of adipocytes per depot (Fig. 4b) or in the average
size of adipocytes between WT (SAT diameter= 40.4 ± 17.6 µm,
VAT diameter= 51.7 ± 24.7 µm, n= 7) and KO (SAT diameter =
36.1 ± 12.1 µm, VAT diameter = 56.5 ± 22.8 µm, n= 7) (Fig. 4c).
However, when comparing the size distribution curve of adipocytes
in SAT and VAT, there was a slight increase in the number of small
adipocytes in SAT (Fig. 4a, d, Supplementary Fig. 4G, H) with a
corresponding modest increase in the number of relatively large
adipocytes in VAT (Fig. 4a, e, Supplementary Fig. 4G, I) of Fam13a
KO mice. These results indicate that depot-specific size distribution
of adipocytes may be associated with the presence of Fam13a in
adipose tissue.
To explore if the metabolic influence of Fam13a deletion is
more profound under diet-induced obesity, mice were challenged
with a high-fat diet (HFD) for 12–14 weeks. Male Fam13a KO
mice gained slightly more weight compared to WT (Fig. 4f), while
maintaining a comparable profile of plasma glucose, insulin, free
fatty acids and triglycerides (Supplementary Fig. 6A) as well as a
similar level of response to both glucose and insulin challenge
(Supplementary Fig. 6B, C). Of note, despite higher overall weight
compared to WT mice, male Fam13a KO mice maintained a
lower weight of VAT (Fig. 4g) and a reduced VAT/SAT ratio
(Fig. 4h), indicating a potential role of Fam13a perturbation in
driving a shift of fat deposition away from visceral depots.
Metabolic profiling of Female Fam13a KO mice after HFD
challenge did not show significant changes as observed in male
mice (Supplementary Fig. 7).
Effect of Fam13a KO on subcutaneous adipogenesis of mice.
To gain insight into the cellular mechanisms underlying
Fam13a’s role in fat distribution, we examined the expression and
function of Fam13a in adipocyte development. In WT mice,
Fam13a expression was enriched in primary mature adipocytes as
compared to freshly prepared stromal vascular fraction of cells
(SVFs), which comprise adipocyte progenitor cells (Fig. 5a). After
growing SVFs into confluence (i.e. Day 0) and inducing them to
adipogenic differentiation, Fam13a expression was found to be
elevated during in vitro adipogenesis (Fig. 5a). The identity of
non-fat vs. fat cell fractions and the successful adipogenic dif-
ferentiation of SVFs were confirmed by the distinct expression
pattern of adiponectin-a mature adipocyte-specific gene (Fig. 5b).
Next, the adipogenic potential of SVFs, isolated from SAT of
WT and Fam13a KO mice, were assessed by comparing gene
expression of adipogenic markers (Pparg, Cebpa, Fabp4), ORO
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staining of lipid droplets and intracellular triglyceride levels.
Results from all these methods showed a similar trend toward
induced adipogenesis in Fam13a KO mice, although none
of them reached statistical significance (Fig. 5c–f). The differ-
entiated subcutaneous adipocytes from Fam13a KO mice also
expressed a marginally but not significantly higher level of beige
adipocyte markers (e.g. Pgc1a and Ucp1; Supplementary Fig. 8).
These subtle but noticeable increases in subcutaneous adipocyte
differentiation may be relevant to the distribution shift toward an
increased number of smaller adipocytes in SAT of male Fam13a
KO mice observed earlier (Fig. 4a, d, Supplementary Fig. 4G, H).
There was no difference in subcutaneous adipogenesis between
female WT and KO mice (Supplementary Fig. 5D, E).
To explore the functional consequences of the modestly
improved subcutaneous adipogenesis, we quantified the basal
and insulin-stimulated glucose uptake in newly differentiated cells
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and observed a non-significant trend toward induction of both
basal and insulin-mediated glucose uptake in Fam13a-deficient
adipocytes (Fig. 5g). To elucidate whether this slight increase in
glucose uptake is due to the presence of more differentiated
adipocytes in the culture of Fam13a KO observed above
(Fig. 5c–f), we also performed ex vivo glucose uptake directly
on SAT explants isolated from WT and Fam13a KO mice, and
observed a similar directional trend (Fig. 5h). These data suggest
that adipocytes from Fam13a KO mice, either differentiated
in vitro or natively present in adipose tissue, are functionally
active in depositing glucose and responding to insulin.
Effect of Fam13a KO on gene profiles of mouse adipose tissue.
To understand the effect of Fam13a KO on gene expression in
mouse tissues, we performed RNA sequencing of the VAT, SAT,
and liver transcriptomes in Fam13a KO and WT male and female
mice on chow and HFD. In WT mice, Fam13a was down-
regulated in all three tissues in response to HFD (Fig. 6a).
Next, we performed a differential expression (DE) analysis
across SAT and VAT samples from male mice (N= 32), adjusted
for known (diet, tissue depot, RNA quality parameters) and
hidden covariates (6 uncorrelated PEER factors). We observed
122 DE genes (FDR < 10%) between KO and WT samples
(combined VAT and SAT; Fig. 6b). The DE genes included
several genes previously associated with fat cell biology, including
Klf1418,19 (Fold change 2.3), Agpat220,21 (FC 0.51), Slc7a1022 (FC
0.65), Vegfa23, Celsr224 (FC 2.14), and Fgfr225 (FC 0.49). Further,
we observed an overrepresentation of genes in adipogenesis
pathways among genes overexpressed in KO, corroborating
evidence from our in vitro and in vivo data suggesting that
Fam13a deficiency induces subcutaneous adipogenesis. We also
observed overrepresentation of genes in a NAD+ salvage pathway
among underexpressed genes; this pathway has been discussed
previously in SAT in the context of obesity and weight loss, and
intracellular levels of NAD+ have a role in maintaining the
metabolic status of the cell26. In addition to adipogenesis and
NAD+ salvage pathways, we found an overrepresentation of
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overexpressed genes in fatty acid beta-oxidation and TCA cycle
pathways in SAT from KO animals. There were no significant
pathway enrichments in VAT. In a secondary DE analysis
stratified by fat depot (SAT and VAT; including male and female
samples [N= 23] and adjusting for sex in addition to the
covariates listed above), we found a 13-fold difference in the
number of DE genes in SAT compared to VAT (n= 288 in SAT,
n= 22 in VAT, FDR < 10%), suggesting that Fam13a KO has a
dramatically larger impact on the transcriptome in SAT.
The negative correlation of adipose Fam13a expression with
obesity in a genetically obese and diabetic mouse dataset of
BTBRob/ob was demonstrated through a collaboration with Dr.
Alan Attie’s lab (Supplementary Fig. 9A). Additionally, in these
mouse models, adipose Fam13a expression was negatively
associated with proliferation of cells residing in adipose tissue,
measured by the incorporation of deuterium into newly
synthesized DNA of adipose tissue (Supplementary Fig. 9B). This
negative correlation between Fam13a expression and adipose cell
proliferation may be reflected by the quantity and phenotypic
composition of adipose stromal cells. Within the phenotypic
spectrum of SVFs, the percentage of CD45- non-immune cell
subset, including adipose progenitor cells (APC, CD45- Sca1+
CD31-) and endothelial cells (EC, CD45- Sca1+ CD31+ ),
increased in subcutaneous fat of Fam13a KO mice (Supplemen-
tary Fig. 9C–E). In addition, purified APCs from KO mice tended
to differentiate better into adipocytes, as compared to WT
(Supplementary Fig. 9F, G). These results suggest that Fam13a
expression in SAT is negatively related to the number of adipose
precursors as well as the adipogenic ability of these cells, which is
consistent with our previous result that the crude SVFs of
Fam13a-deficient mice exhibit higher adipogenic potential
(Fig. 5).
Discussion
Our human genetic data coupled with in vivo and in vitro
experiments provide evidence that FAM13A regulates fat dis-
tribution and metabolic traits through its action on adipose tissue.
This selective role of FAM13A is supported by the SAT-specific
FAM13A eQTLs that are associated with a metabolically obese
normal weight phenotype and by the correlation of SAT FAM13A
expression with a range of insulin resistance-related phenotypes.
The inverse relationship between SAT FAM13A gene expression
levels and metabolic health is further supported by both in vivo
and in vitro experimental evidence. In WT mice, endogenous
Fam13a expression in adipose tissue decreased upon HFD
treatment. Male Fam13a KO mice showed a reduction in VAT/
SAT ratio despite increasing more in weight during HFD treat-
ment. Finally, Fam13a-deficient SVFs derived from SAT
demonstrated a tendency towards increased ability to generate
new adipocytes de novo, which may help meet the excess lipid-
storage needs. Together, our experimental data are consistent
with the interpretation suggested by GWAS data: higher FAM13A
expression in adipose tissue may have a negative impact on body
fat distribution.
The anatomic location of excess body fat has an important
impact on metabolic health as higher VAT/SAT ratio- a
measurement of body fat distribution- is associated with higher
cardiometabolic risks independent of absolute fat volumes27.
A high VAT/SAT ratio can also result from low SAT adiposity,
and an inability to appropriately expand SAT is one of the key
factors that links excess caloric intake to insulin resistance28.
Both genetically modified mouse models (e.g. adipose-
specific overexpression of GLUT429 or mitoNEET30) and
pharmacological models (e.g. treatment of the PPARg agonist,
thiazolidinedione31) that exhibit a healthy obese phenotype tend
to display preferential expansion of SAT with improved insulin
sensitivity. In our study, Fam13a KO mice showed a reduction in
VAT/SAT ratio after HFD challenge as compared to WT mice.
The reduced VAT mass and increased adipogenesis program in
SAT may simultaneously downregulate the ratio of VAT/SAT in
Fam13a KO mice.
The biological pathways underlying the differential regulation
of the two fat depots were revealed by analyses of differentially
expressed genes and pathways. SAT of Fam13a KO mice showed
a coordinated overexpression of genes regulating adipogenesis
and genes involved in mitochondrial function, such as beta oxi-
dation, the TCA cycle, electron transport and oxidative respira-
tion. SAT is known to be able to generate beige adipocytes, a
mitochondria-rich and fat-burning adipocyte, while VAT is a
classic depot for white adipocytes with a low number of mito-
chondria and limited ability for adipogenesis32. SGBS isolated
from human SAT, as well as SVFs isolated from mouse SAT,
showed an increased tendency to differentiate into beige adipo-
cytes upon FAM13A knockdown (Supplementary Figs. 3A
and 8). Fam13a depletion in SAT may trigger a more dramatic
change than in VAT by generating more beige adipocytes with
improved mitochondrial efficiency. The increased mitochondrial
metabolism, combined with induced generation of healthy adi-
pocytes, preserves insulin sensitivity, despite obesity. In-depth
metabolic and thermogenic functional studies at various stages of
adipocyte development are warranted to fully reveal the invol-
vement of FAM13A on white/beige adipocyte fate determination
and metabolism.
The biological function of FAM13A protein and the mechan-
isms through which FAM13A mediates adipogenesis remain
poorly understood. Based on the amino acid sequence homology,
FAM13A contains RhoGAP domain, an evolutionary conserved
protein domain of GTPase activating proteins for small
GTPases (Rho/Rac/Cdc42-like)33. Data from others suggests that
Rho GTPase signaling regulates adipogenesis34. Additionally,
WNT/β-catenin signaling is known to inhibit adipogenesis35.
Tang et al. suggests a potential role of FAM13A in regulating
adipose precursor number, potentially via WNT/β-catenin sig-
naling36. Future studies are necessary to uncover the mechanistic
link between FAM13A and adipogenesis.
Consistent with our data, additional studies have indicated
that adipose tissue is the primary site for FAM13A action med-
iating downstream metabolic functions. Wardhana et al.37 and
Tang et al.36 showed a negative correlation of adipose Fam13a
expression with diet-induced obesity in mice, in agreement with
our data. Lundbäck et al.38 and Tang et al.36 noted FAM13A as a
negative regulator of adipogenesis by using different immorta-
lized cell models and genetic manipulation approaches: Lundbäck
et al.38 showed that siRNA knockdown of FAM13A during a
specific differentiation window of human mesenchymal stem cells
(from day 4 to day 7) induced genes indicative of adipogenesis
(CEBPA, PPARG)38, while Tang et al.36 showed that over-
expression of Fam13a in mouse 3T3-L1 cells led to apoptosis of
preadipocyte and diminished its conversion to adipocytes.
Regarding whole-body metabolism, Wardhana et al.37. showed no
difference in food intake, oxygen consumption, respiratory
exchange ratio, physical activity and body temperature (under
room temperature) between WT and Fam13a-overpression mice
after 14-week HFD challenge. Wardhana et al.37 observed a
modest but significant insulin resistance and glucose intolerance
in Fam13a KO mice, while we and Tang et al.36 detected no
difference in either insulin sensitivity or glucose tolerance
between WT and Fam13a KO mice under both chow and HFD,
despite a slightly increased adiposity in Fam13a KO mice after
HFD. These discrepancies might be explained by variations in
experimental conditions such as the sex of the mice used for
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specific experiments, the content of fat and sugar in diets, and the
fat percentage achieved after different lengths of HFD challenges
started at various ages of animals. More inclusive studies based on
consistent experimental conditions are required to fully evaluate
the metabolic consequence of Fam13a deficiency. While our
findings and other studies give support to the notion that adipose
tissue mediates FAM13A action, the metabolic phenotypes of
whole-body Fam13a KO mice are subtle. Adipose-specific
knockouts of Fam13a would be useful to study the role of
Fam13a specifically in adipose tissue and its causal impact on
systemic metabolism.
Sex dimorphism in the association of FAM13A with body fat
distribution is observed in both humans and mice. In human
GWAS, the WHRadjBMI locus harboring FAM13A variants
showed a stronger effect in women than in men. Sex dimorphism
in the genetic regulation of fat distribution may be related to the
difference in body fat shape between the sexes39. In mouse
models, while in male mice there was a difference in VAT/SAT
between WT and Fam13a KO mice upon HFD, no significant
phenotypic effects of Fam13a deficiency were observed in female
mice. Although current translational investigation on fat dis-
tribution and its metabolic consequences relies on rodent models,
they may not faithfully mimic all aspects of human fat biology
due to differences in anatomical location and function of fat
depots between species39.
Our current model in humans is that FAM13A negatively
regulates adipocyte development. Carriers of the FAM13A sus-
ceptibility alleles associated with higher WHR and fasting insulin
levels express higher levels of FAM13A in SAT, despite having a
lower overall body fat compared to noncarriers. In noncarriers, in
response to caloric excess (such as HFD) there is systemic
demand for fat storage and downregulation of FAM13A in SAT
may stimulate preadipocytes of subcutaneous origin to differ-
entiate into new and healthy adipocytes for improved fat storage.
In carriers of FAM13A risk alleles, FAM13A expression in SAT
remains high after calorie challenge which may limit the healthy
expansion of SAT compartment through de novo adipogenesis,
thus diverting lipid deposition into VAT. Therefore, we propose
that FAM13A alleles associated with increased SAT FAM13A
expression may predispose an individual to a damaging body fat
distribution pattern. This pattern has been termed a “lipody-
strophy-like” pattern in the literature4,5.
In conclusion, our work suggests a novel role of FAM13A in
adipocyte differentiation and function. We have provided evi-
dence that the presence of FAM13A risk alleles is correlated with
higher FAM13A expression in SAT that, in turn, is associated
with unfavorable body fat distribution. Future studies to under-
stand the molecular mechanism of action of FAM13A will be
important to gain insights on how fat is distributed in health and
cardiometabolic diseases.
Methods
UK Biobank and Gene ATLAS. The UK Biobank is a prospective cohort study of
approximately 502,000 individuals conducted between 2006 and 2010. The data
includes genotype and detailed phenotype information; the study was approved by
the North West Multi-Center Research Ethic Committee, and all participants
provided written consent.
Fine-mapping and colocalization. We characterized the role of FAM13A across
tissues in humans by integrating IR-related trait GWAS data with tissue-specific
gene expression from the Genotype Tissue Expression project (v7). We first per-
formed Bayesian fine-mapping using the FINEMAP algorithm to determine pos-
terior probabilities of each variant in the locus driving the association signal.
We then used the top-variant ranked by posterior probability for further analyses.
We performed colocalization analysis of FAM13A gene expression in subcutaneous
adipose tissue (SAT), visceral adipose tissue (VAT), liver and skeletal muscle with
seven traits using eCAVIAR. The seven traits included were WHRadjBMI, trigy-
ceride levels, HDL, FI, FIadjBMI, fasting glucose, and BMI. We modified the
colocalization posterior probability (CLPP) computed in eCAVIAR to consider a
locus as colocalized if the GWAS and eQTL predicted causal SNPs are in strong
LD. The modified CLPP (mCLPP) was computed as
mCLPP ¼
X
i;j <N
giejLDij
where gi and ej are the probabilities that the ith and jth SNPs are causal GWAS and
eQTL SNPs respectively, and LDij is the LD R2 between the two SNPs.
Enrichment for epigenomic annotations. We performed a statistical enrichment
analysis for epigenomic marks in which we defined a 99% credible set consisting of
16 linked variants at the FAM13A locus that are most likely to be responsible for
driving the association at this locus. We used FINEMAP posterior probabilities to
define this set – variants were included as long as their cumulative fine-mapping
posterior probability for the SAT eQTL signal was ≤0.99. We used permutations
(n= 1000) to estimate enrichment using the mean finemapping posterior prob-
ability of variants that overlapped an annotation as a test statistic. We shifted the
annotations randomly by a maximum of 500 kb for each permutation and esti-
mated an enrichment p-value using the empirical distribution.
PheWAS in UK Biobank. We performed a phenome-wide association study
(PheWAS) to study the phenotypic effects of the FAM13A eQTLs in 337,536
individuals of the UK Biobank. Instead of the leading finemapped variant
rs9991328, we used rs1377290 (LD R2 = 1.0) as a proxy. We used a linear model
adjusted for age, sex, genotyping array and 10 principal components to study the
association of rs1377290 with 278 predefined phenotypes including hospitalization
and procedure codes, self-reported variables, and physical and functional mea-
surements40. We performed additional lookups of phenotypic associations using
the Gene ATLAS (http://geneatlas.roslin.ed.ac.uk/).
METSIM and STAGE. THe METabolic Syndrome In Men (METSIM) Study is a
resource for studies of metabolic and cardiovascular diseases14. For the METSIM
expression arrays, there were 770 individuals in total. There were 1400 biopsies
taken, although only 770 subjected to the expression arrays. These were all men
collected from Kupio Finland, age 45–73 (http://www.nationalbiobanks.fi/index.
php/studies2/10-metsim)14. The Stockholm Atherosclerosis Gene Expression
(STAGE) Study is a multi-organ expression profiling (gene network across seven
vascular and metabolic tissues) to uncover a gene module in coronary artery dis-
ease gene16,41. STAGE consisted of 105 individuals (both genders) collected from
Sweden and Estonia, age 58–74. In this study, 72 individuals were subjected to
expression arrays using the HuRSTA-2a520709 Affy platform16. Human gene-by-
gene and gene-by trait correlations were performed on adipose tissue expression
arrays data from the METSIM study13,19, as well as adipose and liver expression
arrays within the STAGE study16,41. These individual X gene expression matrices
were used for correlations, which were performed using the WGCNA package42 in
R and corrected using a 5% FDR.
T2D Knowledge Portal. This portal enabled us to browse and analysis of human
genetic information linked to FAM13A locus. (Accelerating Medicines Partnership,
AMP). http://www.type2diabetesgenetics.org/.
Animal care and experiments. All animal studies were reviewed and approved
prior to commencement of the activity by the Administrative Panel on Laboratory
Animal Care (APLAC) at Stanford University. We obtained Fam13a mice, ori-
ginally created from ES cells of KOMP Repository in which exon 5 of the Fam13a
gene was flanked by LoxP sites, as a contribution from Jin’s lab43 (Department of
Comparative Biosciences, University of Illinois at Urbana–Champaign, Urbana,
IL). Control (WT) and KO mice were developed on C57BL6 background.
Fam13a KO mice were housed at Stanford Animal Facility, with a 12-h light/
dark cycle, in a pathogen-free facility. Mice (control and KO) were fed with either
standard rodent chow diet (Teklad Calories from Protein 24%, from Fat 18%, from
Carbohydrate 58%) or high-fat diet (HFD, Research Diets, Inc., D12451, Protein
20% kcal, Fat 45% kcal, carbohydrate 35% kcal), plus water ad libitum. They
were fed on HFD beginning at 8-weeks-old for 14 weeks until they were killed at
22-weeks-old. Adipose tissue from two depots, gonadal fat (equivalent to VAT) and
inguinal fat (equivalent to SAT), was harvested and weighed. Blood was also
collected. Harvested tissue was either snap frozen and stored in −80 °C for RNA
and protein extraction or fixed in 4% PFA for staining and immunohistochemistry
evaluation.
Hematoxylin and Eosin staining. Mice were overnight fasted, bled and weighed
before sacrificing. VAT, SAT, and liver were harvested, weighed, and fixed in 10%
Neutral Buffered Formalin (Thermo Scientific). Tissues were left in fixative for 24 h
and then dehydrated in 70% ethanol. Dehydrated tissue underwent standard H&E
statning44 in the Stanford Animal Histology facility, as follows: Xylene x3, 2 min
each; 100% Ethanol 2 min; 100% Ethanol 1 min; 95% Ethanol x2, 1 min each; 80%
Ethanol, 1 min; Running tap water, 1 min; Harris Hematoxylin, pH 2.5, 10 min;
Running tap water, 1 min; Clarifier (1% HCl in 70% EtOH) 20 s; Running tap
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water, 5 min; Bluing reagent (~0.5% Ammonium Hydroxide in diH2O); Running
tap water, 3 min; 95% Ethanol 1 min; Eosin, 95% Ethanol solution, pH 4.6, 2 min;
95% Ethanol x3, 30 sec each; 100% Ethanol x3, 2 min each; Xylene x3, 2 min each;
Cover slipped with Cytoseal XYL.
Quantification of adipocyte size and number. Briefly, microphotographs of H&E
stained adipose tissue blocks were acquired from an optical microscope (Zeiss
Axioplan2) at 20x magnification and images were captured with a Leica DC500
camera and a NIS Elements software. ImageJ software with the H&E color
deconvolution plugin was used to determine the size of the adipocytes and the
number of adipocytes within a certain diameter range by two individuals in a
double blinded manner. Four fields of view for SAT slides and six fields of view for
VAT slides were quantified. SAT and VAT from seven animals per group were
analyzed. A total of 2000–2200 cell diameters were measured by Adiposoft, an
automated software for analysis of adipose tissue cellularity45. The quantification
unit of pixels were converted to microns by Photoshop CS6 (1 pixel= 0.3953 µm
at ×20 objective). Adipocyte number per fat depot was calculated by dividing the
total tissue weight by the mean adipocyte weight46. Total tissue weight was mea-
sured directly after tissue dissection, and the mean adipocyte weight was calculated
by multiplying the mean adipocyte volume by the triglyceride density (0.915 g L−1).
The mean volume of adipocyte was calculated from the diameters measured above
by applying the following formula: V= 4/3π (D/2)3.
Glucose and insulin tolerance tests. Glucose and insulin tolerance tests were
performed on 3 to 4-month-old mice47. For GTTs, mice were fasted overnight, and
2 g glucose kg−1 body weight were injected through i.p. For ITTs, mice were fasted
for 6-h and insulin at concentration of 1.0 U kg−1 body weight were i.p. injected.
From the tail vein of conscious animals, blood was collected before i.p. injection,
termed as 0 min, and at 15, 30, 60, and 120 min after injection of either glucose
(GTT) or insulin (ITT). Blood glucose was measured using a glucometer
(TRUEbalance, Nipro Diagnostics, Inc.).
Lipid panel tests. Mice were fasted overnight. Blood was collected by retro-orbital
bleeding from anesthetized mice, using Microhematocrit Capillary Tube (Fish-
erbrand™, Heparinized). After expelled immediately into collection tubes, blood
samples were centrifuged at 6000 rpm for 10 min at 4 °C to collect plasma. Lipids
(includes TG, LDL, HDL, and cholesterol) were measured in plasma samples at the
Stanford Animal Diagnostic Laboratory in the Veterinary Service Center using
standard protocols and instruments. Insulin was measured by using Ultra-Sensitive
Mouse Insulin ELISA Kit (CrystalChem), and Free Fatty Acid was measured by
using Colorimetric Non-esterified Fatty Acid Kit (Wako).
RNA-Seq. RNA was extracted from ~50 mg of liver, visceral and subcutaneous
adipose tissues using RNeasy Lipid Tissue Mini Kit (Qiagen). Library preparation
and RNA sequencing were carried out by using the Illumina TruSeq Stranded
protocol, with an average number of reads per sample as 40 million. Reads were
aligned to the Grcm38 mouse genome using STAR 2.6 software48, and Gencode
M11 mouse gene annotations and counts were obtained using the quantMode
option in STAR. Differential expression analysis was performed using edgeR
3.20.949 with a false discovery rate (FDR) of 10%. Analysis of the transcriptome-
wide effects of Fam13a KO was performed in adipose tissue samples from both
SAT and VAT fat depots of male mice, adjusted for known (diet, fat depot, RIN,
number of days from tissue harvest to RNA extraction) and hidden covariates (6
PEER factors).
F2 ob/ob mice. F2 cohort database derives from B6:BTBR F2 mice that were all
killed at the same age (10 weeks) and were all obese, thereby focusing the study on
genetic differences between the parental strains50. Proliferation of cells in adipose
tissue was measured by the incorporation of deuterium into newly synthesized
DNA, as described previously (http://diabetes.wisc.edu/index.php).
Isolation and culture of SVFs from adipose tissue. Isolation of SVF and adi-
pocyte fraction from adipose tissue, as well as adipogenic differentiation of SVFs
were performed as described below51. In brief, adipose tissue was minced into small
pieces and digested with 0.2% type I collagenase (Life Technologies #17100)
containing 4% BSA for 45 min at 37 °C under continuous shaking at 115 rpm. Cell
suspension was then passed through a gauze, span at 200 × g for 5 min. Floating
adipocyte fraction was collected for RNA extraction, whereas cell pellet was
resuspended in ACK lysing buffer (Thermo Scientific #A1049201) for 10 min at
room temperature before adding complete growth medium (DMEM/F12 with 10%
FBS and 1% penicillin-streptomycin) to stop the reaction. The resulting suspension
was filtered through 100μm strainers. After centrifuging at 200 × g for 5 min, the
pellets were resuspended, with one small aliquot saved for RNA extraction and the
rest of the cells cultured for adipogenic differentiation. In total, 5–7 days post-
seeding, confluent SVF cells were subjected to adipogenesis by using 0.5 mM
IBMX, 1 μM dexamethasone, 10 μg ml−1 insulin and 2.5 μM rosiglitazone for
2 days, followed by supplementation of 10 μg ml−1 insulin alone for an additional
8 days.
Culture and differentiation of human SGBS preadipocytes. Human Simpson-
Golabi-Behmel syndrome (SGBS) preadipocytes17 (a gift from Dr. Martine
Wabitsch, University of Ulm) were cultured in DMEM/F12 supplemented with 10%
fetal bovine serum, 8 μgml−1 biotin, 4 μg ml−1 pantothenic acid and antibiotics
(100 UmL−1 penicillin and 0.1mgmL−1 streptomycin). To initiate adipogenic
differentiation of SGBS preadiocytes, serum-free DMEM/F12 was supplemented
with 8 μg ml−1 biotin, 4 μg ml−1 pantothenic acid, 10 µg mL−1 transferrin, 20 nM
insulin, 100 nM cortisol, 0.2 nM triiodothyronine (T3), 25 nM dexamethasone,
250 µM IBMX and 2 µM rosiglitazone for 4 days. Cells were thereafter incubated in
serum-free medium containing all the components above except dexamethasone,
IBMX, and rosiglitazone52. Adipocyte functional assays, including glucose uptake
and lipolysis, were tested in differentiated SGBS adipocyte on Day 12.
CRISPRi knockdown of FAM13A in SGBS preadipocytes. For the dCas9-KRAB
expressing construct, we used pHR-SFFV-KRAB-dCas9-P2A-mCherry (Addgene
#60954) which expressed an N-terminal KRAB-dCas9 fusion protein and mCherry.
For the sgRNA expression vector, we used a lentiviral U6 based system (pU6-
sgRNA EF1alpha-puro-T2A-GFP, a gift from Jonathan Weissman) which coex-
pressed GFP and a puromycin-resistance cassette separated by a T2A sequence
from the EF1alpha promotor. Three sgRNA sequences targeting FAM13A and one
scramble sgRNA control sequence were selected from the human CRISPRi v2
(hCRISPRi-v2) library53 and cloned into the lentiviral U6 based expression vector
backbone54. Final individually cloned gRNA constructs were transformed into
chemically competent cells (NEB #C2987) and extracted by a QIAprep Spin
Miniprep Kit (QIAGEN #27106) for downstream lentivirus production. The
sgRNA sequences of all plasmids were confirmed by Sanger sequencing: Scrambled
sgRNA: GCTGCATGGGGCGCGAATCA; sgFAM13A_1: GACGCTTTCTGAGA
GAATGG; sgFAM13A_2: GTCCCAATGCAAAGGCCCCA; sgFAM13A_3: GTC
CGCTGAACCCACATGGC.
Lentivirus was produced in HEK293T cells (ATCC: CRL-3216™) maintained in
DMEM with 10% FBS, 1% Pen-Strep and 2 mM GlutaMAX™ (Invitrogen). Cells
were seeded at 4 million per 10 cm dish, and transfected the following day with
either the dCas9-KRAB vector (9 μg) or the sgRNA vector (9 μg) along with the
envelope vector pMD2.G (1 μg, Addgene #12258) and the packaging vector
pCMV-dR8.91 (8 μg, a gift from Jonathan Weissman) using Lipofectamine 3000
(Invitrogen). In all, 6–14 h after transfection, culture medium was refreshed. For
the lentivirus generation of dCas9-KRAB, 1:500 volume of ViralBoost™ Reagent
(ALSTEM #VB100) was supplemented into one volume of the fresh culture
medium. In all, 48 h later, supernatant was collected and filtered through 0.45 μm
filters. sgRNA virus was frozen immediately in −80 °C, while dCas9-KRAB virus
was concentrated by 10-fold using Lentivirus Precipitation Solution (ALSTEM
#VC100) before frozen.
To construct CRISPRi knockdown of FAM13A, SGBS preadipocytes at 70%
confluence were co-transduced by concentrated dCas9-KRAB virus (1 volume) and
unconcentrated gRNA virus (2 volume), along with SGBS culture medium (3
volume) supplemented with polybrene (8 μg ml−1 in total mixture). In all, 72 h
later, cells were harvested and sorted by flow cytometry using a BD Influx™ Sorter.
Briefly, cells were first selected by size, on the basis of forward scatter (FSC) and
side scatter. Cells were then gated on both FSC and SSC singlets to ensure that
individual cells were analyzed. Wild-type SGBS preadipocytes were used as the
negative control to determine background fluorescence levels. Collection gate was
set on double-positive population of mCherry (dCas9-KRAB expression) and GFP
(gRNA expression) cells. Sorted cells were expended in culture, grown into
confluence before induction of adipogenic differentiation.
Flow cytometry and fluorescence-activated cell sorting. Antibodies used
include CD45-FITC (eBioscience 11-0451-81), CD31-PE-Cy7 (eBioscience 25-
0311-82) and Sca1-APC (eBioscience 10811). Freshly isolated SVFs were resus-
pended in FluoroBrite™ DMEM media (Thermo Fisher A1896701) supplemented
with 2% FBS at 10 million cells per mL for antibody staining, followed by FACS.
Dilution factors for the antibodies were: 1:200 for CD45-FITC, 1:100 for CD31-PE-
Cy7, and 1:100 for Sca1-APC. Samples were analyzed and sorted on a BD Influx™
Sorter. Cell gating was based on the unstained controls. Live and single cells were
separated by forward scatter (FSC) and side scatter analysis. Cells were sorted into
Trizol for gene expression analysis or into complete media for cell culture. FACS
files were analyzed using FlowJo v.9.
Glucose uptake. Mouse SVFs and human SGBS preadipocytes were grown and
differentiated in 24-well plates, and starved in serum-free and glucose-free
medium for 3 h prior to the assay. After washing 2 times with pre-warmed KRH
buffer [50 mM HEPES, 137 mM NaCl, 4.7 mM kCl, 1.85 mM CaCl2, 1.3 mM
MgSO4, pH= 7.4], cells were treated with or without insulin (100 nM) in KRH
buffer for 30 min, followed by the addition of 1 μCi ml−1 [3H] 2-Deoxy-D-Glucose
(PerkinElmer) and 100 μM 2-Deoxy-D-Glucose (Cayman) for 15 min. Reactions
were terminated by washing the cells with ice-cold KRH buffer for three times.
Cells were then lysed by M-PER™Mammalian Protein Extraction Reagent (Thermo
Scientific), and the incorporated radioactivity was determined by liquid scintilla-
tion counting. A small aliquot of each cell lysate was used for protein quantification
and normalization of radioactivity counting. For ex vivo glucose uptake on adipose
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tissue explants, ~20 mg tissues were weighed and cultured in one of the 24-well.
After following the same procedure as described above, tissues were digested with
0.5 M NaOH overnight. Radioactivity measurements on the tissue lysates were
normalized against the tissue weight per well.
Lipolysis. Glycerol release into the culture medium was used as an index of
lipolysis. Differentiated SGBS adipocytes were starved in DMEM/F12 contain-
ing 2% fatty acid-free BSA for 3 h prior to the assay. Then, the same medium
was refreshed with the addition of either vehicle (DMSO) or isoproterenol (ISO,
100 nM). After 3 h of incubation, 100 μl culture medium was transferred to a
96-well, and 100 μl of Free Glycerol Reagent (Sigma-Aldrich #F6428) was added to
each well. Plates were incubated at room temperature for 15 min and the absor-
bance was read at 540 nm. Glycerol concentration was corrected by the protein
content of the cells in the same well.
Triglyceride quantification assay. Intracellular triglycerides in differentiated
adipocytes were extracted and homogenized in 5% NP-40. Cell suspension was
centrifuged at 10,000 × g for 10 min at 4 °C. Supernatant was then diluted by 1:3
and triglyceride concentration at 550 nm absorbance was measured by using the
Triglyceride Colorimetric Assay Kit (Cayman #10010303). Triglyceride levels were
presented by normalizing against the protein content.
Oil Red O staining and semi-quantification. Differentiated adipocytes were fixed
with 10% formalin for at least 1 h. The cells were then rinsed with 60% isopropanol
for 5 min followed by the 15-min incubation with freshly prepared ORO working
solution (composed of 4 parts water and 6 parts 0.35% ORO dye in isopropanol).
After four times washing with water, images were acquired under the light
microscope. ORO was then extracted from fixed cells with 100% isopropanol,
followed by OD measurement at the absorbance of 500 nm. DNA content of the
fixed cells was extracted by QIAamp DNA FFPE Kit (Qiagen #56404). ORO
content was presented by normalizing against the DNA content.
Reverse transcription and qPCR analysis. Total RNA was extracted using TRIzol
reagent (Invitrogen). RNA was converted to cDNA using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Quantitative PCR reactions were
prepared with TaqMan™ Fast Advanced Master Mix (Thermo Fisher Scientific) and
performed on ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). Data were
normalized to the content of Cyclophilin A (PPIA), as the endogenous control.
TaqMan primers obtained from Thermo Fisher Scientific were: LEP
(Hs00174877_m1), PPARG (Hs01115513_m1), CEBPA (Hs00269972), UCP1
(Hs01084772), PPIA (Hs04194521_s1), Adipoq (Mm00456425_m1), Pparg
(Mm00440940_m1), Cebpa (Mm00514283_s1), Fabp4 (Mm00445878_m1), Ppia
(Mm02342430_g1); TaqMan primers obtained from IDT were: FAM13A (HS.
PT.58.3237208), ADIPOQ (Hs.PT.58.39189358), and PGC1A (Hs.PT.58.14965839),
Fam13a (Mm.PT.56a.7855516).
Gene enrichment and pathway analysis. The GO and pathway analysis of human
and mice expression data were assessed by ConsensusPathDB-human and Con-
sensusPathDB-mouse, which are fully accessible online (http://cpdb.molgen.mpg.
de/CPDB.15).
Statistical analysis. For comparison of plasma biochemicals, body and tissue
weights of WT and KO mice, two-tailed parametric T-test were applied using
GraphPad Prism version 7.00 (GraphPad Software, La Jolla California USA). A p
value of <0.05 (*), <0.01 (**) and <0.001 (***) were considered significant and
asterisked in the relevant plots. Between-group differences in distribution curves
for adipocyte diameter were analyzed using the Kolmogorov–Smirnov test, which
takes into account the ordering (i.e., cell diameter) of the categories and is therefore
a suitable test for analysis of curve shifts.
The analysis of expression data in METSIM follows previously published
results14,19. Statistical methods for analysis of data from the STAGE cohort have
already been published16,41. Expression data were considered significant with 5%
FDR. To show adjusted relationships between FAM13A expression adjusted for
BMI and clinical traits, we implemented the following: A linear model was
constructed between normalized probe levels across the population and BMI (using
the base R function lm), and extracted residuals were correlated against indicated
clinical traits. Biweight midcorrelation and corresponding student p values for this
relationship were calculated using the R package WGCNA.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-Seq data have been deposited to the National Center for Biotechnology
Information Gene Expression Omnibus and are available at GSE137022. All the data
related to METSIM and STAGE cohorts are available at GSE70353, PMID 28119442,
PMID 28573393, PMID 28257690, PMID 19997623 and URL http://www.
nationalbiobanks.fi/index.php/studies2/10-metsim. The GWAS data for bodyfat %,
FIadjBMI and WHRadjBMI are publicly available at https://www.ebi.ac.uk/gwas/. For the
eQTL tracks, the variant level associations are available at https://gtexportal.org/home/
datasets. PheWAS data were obtained from UK Biobank dataset and is available through
an application process at https://www.ukbiobank.ac.uk/register-apply/. Data for the
epigenetic annotations is publicly available and can be downloaded at GSM916066,
GSM906397, and GSM906395. Source Data underlying Figs. 3–6 and Supplementary
Figs. 2–9 are provided as a Source Data file. All other data are included in the article file
and its supplementary information or available upon request.
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